LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

Search

Johnson and Johnson

Closed

Sector Healthcare

146.98 -0.66

Overview

Share price change

24h

Current

Min

146.6

Max

148.28

Key metrics

By Trading Economics

Income

-2B

2.7B

Sales

50M

23B

P/E

Sector Avg

24.52

59.526

EPS

2.42

Dividend yield

3.103

Profit margin

11.973

EBITDA

-2.4B

5.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+14.94 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.10%

2.33%

Next Earnings

22 Jan 2025

Next Dividend date

4 Mar 2025

Next Ex Dividend date

18 Feb 2025

Market Stats

By TradingEconomics

Market Cap

-1.2B

349B

Previous open

147.64

Previous close

146.98

News Sentiment

By Acuity

16%

84%

24 / 392 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jan 2025, 12:11 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 Jan 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

13 Jan 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 Jan 2025, 20:12 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 Jan 2025, 16:18 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 Jan 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 Jan 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 Jan 2025, 13:35 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 Jan 2025, 12:25 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 Jan 2025, 11:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 Jan 2025, 11:56 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 Jan 2025, 11:45 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 Jan 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 Jan 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 Jan 2025, 11:42 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 Jan 2025, 11:41 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 Jan 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 Jan 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 Jan 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 Jan 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 Jan 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 Jan 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 Jan 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 Jan 2025, 10:55 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 Jan 2025, 10:41 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

2 Jan 2025, 14:00 UTC

Top News

Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops -- IBD

13 Dec 2024, 20:55 UTC

Top News

J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- Update

13 Dec 2024, 20:31 UTC

Top News

J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- WSJ

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

9 Dec 2024, 02:14 UTC

Top News

Apple Tops the List of Best-Managed Companies of 2024 -- Journal Report -2-

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

14.94% upside

12 Months Forecast

Average 169 USD  14.94%

High 185 USD

Low 160 USD

Based on 11 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

4

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

144.19 / 147.77Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

24 / 392 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.